Abstract
7557Background: In GALLIUM (NCT01332968; 1202 follicular lymphoma pts), investigator-assessed progression-free survival (PFS) was significantly prolonged by first-line obinutuzumab (G)- vs rituxima...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
